• Aliases: INCB18424, Jakavi (Canada)
    • An oral kinase inhibitor that inhibits JAK1 and JAK2
    • FDA approved for intermediate- or high-risk myelofibrosis; also being investigated in phase 2 trials for lymphomas, relapsed/refractory leukemias, pancreatic cancer, triple-negative or inflammatory breast cancer, and polycythemia vera
    • Recommended dose: Platelets ≥200,000/mm3, start 20 mg PO b.i.d.; platelets ≥ 100,000/mm3, start 15 mg PO b.i.d.; platelets ≥ 50,000/mm3, start 5 mg PO b.i.d.; may titrate all doses in increments of 5 mg PO b.i.d every 2 weeks to maximum dose of 25 b.i.d with or without food
    Other topics in Targeted and Immunotherapy Agents